Molecular prediction of progression in patients with conservatively managed prostate cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84126
Title:
Molecular prediction of progression in patients with conservatively managed prostate cancer.
Authors:
McIntyre, Iain G; Clarke, Robert B; Anderson, Elizabeth; Clarke, Noel W ( 0000-0001-7776-8059 ) ; George, Nicholas J
Abstract:
OBJECTIVES: To report our results with the use of reverse transcriptase-polymerase chain reaction (RT-PCR) as a potential predictor of prostate cancer (CaP) progression in patients managed with watchful waiting. There has been much recent debate about the safety of treating older patients with localized CaP with watchful waiting. The RT-PCR is an assay that can detect small numbers of prostate cells in circulating blood. METHODS: Blood samples were taken from male and female control patients and from patients with advanced, hormone-treated and untreated localized (watchful-waiting) CaP. Sensitive nested RT-PCR assays were carried out on these samples using primers for both prostate-specific antigen (PSA) and prostate-specific membrane antigen mRNA. RESULTS: Fifty-one blood samples were taken from patients managed with watchful waiting. Fourteen of these had positive RT-PCR results. These patients had a significantly higher PSA velocity than did the patients with negative RT-PCR results. Circulating prostate cells were detected in 18 of 24 patients with advanced CaP, 2 of 34 patients with stable, hormone-treated CaP, and in none of the negative controls. The assay was able to detect 20 LNCaP cells reliably when added to a 5-mL volunteer blood sample. CONCLUSIONS: A significant minority (27%) of patients with untreated localized CaP had detectable circulating prostate cells, and these patients tended to have a progressively rising serum PSA level. Despite low-grade disease and sometimes low serum PSA values, these patients may be at risk of early metastatic progression. RT-PCR, in conjunction with existing prognostic tests, may be of use in predicting which "watchful-waiting" patients are at risk of early progression.
Affiliation:
Department of Urology, University Hospital of South Manchester, Withington Hospital, Manchester, United Kingdom.
Citation:
Molecular prediction of progression in patients with conservatively managed prostate cancer. 2001, 58 (5):762-6 Urology
Journal:
Urology
Issue Date:
Nov-2001
URI:
http://hdl.handle.net/10541/84126
PubMed ID:
11711356
Type:
Article
Language:
en
ISSN:
1527-9995
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMcIntyre, Iain Gen
dc.contributor.authorClarke, Robert Ben
dc.contributor.authorAnderson, Elizabethen
dc.contributor.authorClarke, Noel Wen
dc.contributor.authorGeorge, Nicholas Jen
dc.date.accessioned2009-10-13T09:20:06Z-
dc.date.available2009-10-13T09:20:06Z-
dc.date.issued2001-11-
dc.identifier.citationMolecular prediction of progression in patients with conservatively managed prostate cancer. 2001, 58 (5):762-6 Urologyen
dc.identifier.issn1527-9995-
dc.identifier.pmid11711356-
dc.identifier.urihttp://hdl.handle.net/10541/84126-
dc.description.abstractOBJECTIVES: To report our results with the use of reverse transcriptase-polymerase chain reaction (RT-PCR) as a potential predictor of prostate cancer (CaP) progression in patients managed with watchful waiting. There has been much recent debate about the safety of treating older patients with localized CaP with watchful waiting. The RT-PCR is an assay that can detect small numbers of prostate cells in circulating blood. METHODS: Blood samples were taken from male and female control patients and from patients with advanced, hormone-treated and untreated localized (watchful-waiting) CaP. Sensitive nested RT-PCR assays were carried out on these samples using primers for both prostate-specific antigen (PSA) and prostate-specific membrane antigen mRNA. RESULTS: Fifty-one blood samples were taken from patients managed with watchful waiting. Fourteen of these had positive RT-PCR results. These patients had a significantly higher PSA velocity than did the patients with negative RT-PCR results. Circulating prostate cells were detected in 18 of 24 patients with advanced CaP, 2 of 34 patients with stable, hormone-treated CaP, and in none of the negative controls. The assay was able to detect 20 LNCaP cells reliably when added to a 5-mL volunteer blood sample. CONCLUSIONS: A significant minority (27%) of patients with untreated localized CaP had detectable circulating prostate cells, and these patients tended to have a progressively rising serum PSA level. Despite low-grade disease and sometimes low serum PSA values, these patients may be at risk of early metastatic progression. RT-PCR, in conjunction with existing prognostic tests, may be of use in predicting which "watchful-waiting" patients are at risk of early progression.en
dc.language.isoenen
dc.subjectProstatic Canceren
dc.subjectCirculating Cancer Cellsen
dc.subject.meshAged-
dc.subject.meshCase-Control Studies-
dc.subject.meshDisease Progression-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplastic Cells, Circulating-
dc.subject.meshProstate-Specific Antigen-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction-
dc.subject.meshSensitivity and Specificity-
dc.titleMolecular prediction of progression in patients with conservatively managed prostate cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, University Hospital of South Manchester, Withington Hospital, Manchester, United Kingdom.en
dc.identifier.journalUrologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.